This invention relates to novel substituted 1,4-benzodioxine compounds having antidiabetic, andihyperglycemic, and antiobesity properties represented by the formula ##STR1## wherein R.sup.1 and R.sup.6 are independently hydrogen, C.sub.1 to C.sub.6 alkyl, trifluoromethyl, cyano, C.sub.1 to C.sub.6 alkoxy, or halogen; R.sup.2 is hydrogen or C.sub.1 to C.sub.6 trialkylsilyl; R.sup.3 is hydrogen or C.sub.1 to C.sub.6 alkoxycarbonyl; or R.sup.2 and R.sup.3 are joined to form the oxazolidinone ring ##STR2## R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1 to C.sub.6 alkyl; R.sup.7 and R.sup.8 are independently hydrogen OR.sup.9 or NR.sup.10 R.sup.11 ; R.sup.9 is hydrogen, C.sub.1 to C.sub.12 alkyl, C.sub.1 to C.sub.12 cycloalkyl, C.sub.1 to C.sub.12 silylalkyl, phenyl, naphthyl, phenyl C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkoxy C.sub.1 to C.sub.6 alkyl, pyridyl, thiophenyl, furanyl, imidazolyl, oxazolyl, --CHR.sup.12 COOR.sup.13, --CHR.sup.12 C(O)R.sup.13, --CHR.sup.12 CONR.sup.10 R.sup.11, --CHR.sup.12 OCOOR.sup.13, or --CHR.sup.12 OC(O)R.sup.13 ; R.sup.10 and R.sup.11 are independently hydrogen, C.sub.1 to C.sub.12 alkyl, phenyl, naphthyl, phenyl-C.sub.1 to C.sub.6 alkyl, furanylalkyl, or alkoxycarbonylalkyl; R.sup.12 and R.sup.13 are independently hydrogen, C.sub.1 to C.sub.12 alkyl, phenyl, naphthyl, or phenyl-C.sub.1 to C.sub.6 alkyl; and the pharmaceutically acceptable salts thereof, a salt thereof; an enantiomer thereof, the racemic mixtures thereof, and the diastereomeric mixtures thereof. The present invention also relates to a pharmaceutical composition, and methods for treating diabetes and/or hyperglycemia and/or obesity in mammals and producing lean meat in edible domestic animals.
This application claims the benefit of priority of provisional application number 60/034,085 filed on Dec. 30, 1996.
This is a divisional of copending application(s) Ser. No. 08/993,481 filed on Dec. 18, 1997, now U.S. Pat. No. 5,965,607, the entire disclosure of which is hereby incorporated by reference.